OM302 / OncoMyx Therap - LARVOL DELTA

OncoMyx Presents New Data at AACR 2022 Demonstrating Multi-Armed Myxoma Virus Coordinates Tumor-Killing by Activating Innate and Adaptive Immune Responses (Businesswire) - "The data presented at AACR 2022 demonstrate that OncoMyx’s myxoma virus multi-armed with IL-12 and decorin infects and kills human multiple myeloma cells in vitro and demonstrates dose responsive efficacy after intravenous (IV) administration in a mouse model of multiple myeloma."

Preclinical • Hematological Malignancies • Oncology

OncoMyx Presents New Data at SITC 2021 Demonstrating the Potential of a Multi-Armed Myxoma Virus as a Novel Oncolytic Immunotherapy for Solid Tumors and Heme Malignancies (Businesswire) - "OncoMyx Therapeutics...announced the presentation of new preclinical data at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting & Pre-Conference Programs (SITC 2021) being held November 10-14, 2021, both virtually and in Washington, D.C. The data presented show myxoma multi-armed with decorin and IL-12 infects and kills primary human multiple myeloma cells in vitro and demonstrates efficacy in a mouse model of multiple myeloma."

Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology

OncoMyx Presents at AACR First Data Showing Multi-Armed Myxoma Virotherapy Can Modulate Anti-Tumor Immune Response (Businesswire) - "OncoMyx Therapeutics...announced the presentation of three posters at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place April 10-15, 2021. The data are the first to demonstrate that OncoMyx’s multi-armed myxoma virotherapy upregulates anti-tumor immune response pathways, expresses transgenes in a dose and time-dependent manner, and produces anti-tumor efficacy in a preclinical model of cancer following intravenous (IV) or intratumoral (IT) dosing. In addition, new data show that IV administration of myxoma virus produces minimal anti-myxoma antibodies in vivo in a preclinical model and falls within known safety margins of predicted cytokine exposure using quantitative in silico modeling."

Preclinical • Oncology

OncoMyx Announces Assignment of Foundational Technology and Intellectual Property Portfolio for Oncolytic Myxoma Virus Technology (Businesswire) - "OncoMyx Therapeutics...announced today that The University of Western Ontario (Western) has assigned to OncoMyx the technology and patent rights associated with pioneering research on the use of myxoma virus in the treatment of cancer. This research was led by OncoMyx cofounder Grant McFadden, Ph.D., when he was a Professor at Western and the Robarts Research Institute."

Patent • Oncology

OncoMyx Announces Presentation of Preclinical Efficacy Data of Novel Oncolytic Immunotherapy at SITC 2020 (Businesswire) - “The data are the first to demonstrate preclinical therapeutic efficacy of a multi-armed myxoma virotherapy for the treatment of cancer following intravenous (IV) or intratumoral (IT) delivery alone and in combination with immune checkpoint inhibitors. Efficacy of Oncomyx’s multi-armed myxoma virotherapy was seen in multiple subcutaneous and metastatic syngeneic tumor models, supporting a pan-tumor treatment approach…. Additional data showed evidence of modulation of tumor infiltrating lymphocytes populations, including increased CD8/Treg and M1/M2 macrophage ratios, to favor anti-tumor immunity.”

Preclinical • Oncology

OncoMyx Announces Presentation of Preclinical Data for Novel Oncolytic Virotherapy at AACR Tumor Immunology and Immunotherapy Virtual Conference (Businesswire) - "OncoMyx Therapeutics...announced the presentation of preclinical data at the AACR Virtual Special Conference: Tumor Immunology and Immunotherapy taking place October 19 to 20. The data are the first to demonstrate preclinical therapeutic activity alone and in combination with immune checkpoint inhibitors of the company’s armed myxoma virotherapy in development to improve cancer treatment."

Preclinical • Oncology